Humasis Co

Humasis Co ROE

The Return on Equity (ROE) of Humasis Co (205470.KQ) as of Nov 11, 2026 is -7.26 %. In the previous year, Return on Equity (ROE) was -13.28 % — a change of -45.30% (higher).

ROE

-7.26 %

YoY

-45.30%

Last updated:

In 2025, Humasis Co's return on equity (ROE) was -7.26 %, a -45.30% increase from the -13.28 % ROE in the previous year.

The Humasis Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-5.29 KRW
Jan 1, 2019
-8.04 KRW
Jan 1, 2020
43.17 KRW
Jan 1, 2021
74.85 KRW
Jan 1, 2022
52.67 KRW
Jan 1, 2023
-19.29 KRW
Jan 1, 2024
-13.28 KRW
Jan 1, 2025
-7.26 KRW
The Humasis Co ROE history
YEARROEYoY
-7.26 %-45.30%
-13.28 %-31.16%
-19.29 %-136.62%
52.67 %-29.63%
74.85 %+73.40%
43.17 %-636.64%
-8.04 %+52.10%
-5.29 %-82.52%
-30.25 %-3,070.87%
1.02 %+57.80%
0.65 %+2,168.76%
0.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Humasis Co's Return on Equity (ROE)

Humasis Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Humasis Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Humasis Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Humasis Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Humasis Co stock

Return on Equity (ROE) of Humasis Co is -7.26 % in 2025.

Return on Equity (ROE) of Humasis Co changed from -13.28 % to -7.26 %, representing a -45.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Humasis Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Humasis Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Humasis Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Humasis Co